 - Subjects taking medications that are sensitive to substrates or substrates with a narrow therapeutic range for CYP3A4, CYP2C8, CYP2C9, or CYP2D6CYP2C9, CYP2C19, CYP1A2, Other OATP1B1 Unless willing and able to stop or modify the dosing of the drug or strong inhibitors or inducers of CYP3A4 e.g. cyclosporine, tacrolimus or sirolimus. 